AZTA (Azenta, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by AZTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Olga Pirogova | SVP and CHRO | F | — | — |
| 2026-08-04 | Ephraim Starr | SVP, Gen Counsel & Secretary | Buy | — | — |
| 2026-05-19 | William L Cornog | Director | Buy | — | — |
| 2026-05-18 | Ephraim Starr | SVP, Gen Counsel & Secretary | F | — | — |
| 2026-05-12 | Quentin Koffey | Director | A | — | — |
| 2026-02-06 | William L Cornog | Director | — | — | — |
| 2026-02-06 | Tina Susan Nova | Director | A | — | — |
| 2026-02-06 | Erica McLaughlin | Director | A | — | — |
| 2026-02-06 | Dipal Doshi | Director | A | — | — |
| 2026-02-06 | Martin D Madaus | Director | A | — | — |
| 2026-02-06 | Frank Casal | Director | A | — | — |
| 2026-02-06 | Robyn C Davis | Director | A | — | — |
| 2026-02-06 | William L Cornog | Director | A | — | — |
| 2025-12-03 | John Marotta | President and CEO | A | — | — |
| 2025-11-25 | Martin D Madaus | Director | — | — | — |
| 2025-11-25 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | — | — |
| 2025-11-25 | Ginger Zhou | SVP and GM, Multiomics | A | — | — |
| 2025-11-25 | William L Cornog | Director | — | — | — |
| 2025-11-25 | William L Cornog | Director | Buy | — | — |
| 2025-11-25 | Ephraim Starr | SVP, Gen Counsel & Secretary | A | — | — |
| 2025-11-25 | John Marotta | President and CEO | A | — | — |
| 2025-11-25 | Olga Pirogova | SVP and CHRO | A | — | — |
| 2025-11-17 | Olga Pirogova | SVP and CHRO | F | — | — |
| 2025-11-17 | John Marotta | President and CEO | F | — | — |
| 2025-11-17 | Ginger Zhou | SVP and GM, Multiomics | F | — | — |
| 2025-11-17 | Lawrence Y. Lin | EVP, CFO and Treasurer | F | — | — |
| 2025-11-14 | Ginger Zhou | SVP and GM, Multiomics | Sell | — | — |
| 2025-11-14 | John Marotta | President and CEO | Buy | — | — |
| 2025-11-14 | Alan J Malus | Director | Buy | — | — |
| 2025-11-14 | Olga Pirogova | SVP and CHRO | Sell | — | — |
| 2025-09-12 | John Marotta | President and CEO | Sell | — | — |
| 2025-08-13 | Olga Pirogova | SVP and CHRO | D | — | — |
| 2025-08-13 | Ginger Zhou | SVP and GM, Multiomics | D | — | — |
| 2025-08-12 | Lawrence Y. Lin | EVP, CFO and Treasurer | Buy | — | — |
| 2025-06-04 | John Marotta | President and CEO | A | — | — |
| 2025-06-04 | John Marotta | President and CEO | A | — | — |
| 2025-06-03 | Alan J Malus | Director | A | — | — |
| 2025-05-27 | Ephraim Starr | SVP, Gen Counsel & Secretary | A | — | — |
| 2025-05-20 | William L Cornog | Director | A | — | — |
| 2025-05-12 | John Marotta | President and CEO | A | — | — |
| 2025-05-12 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | — | — |
| 2025-02-13 | Lawrence Y. Lin | EVP, CFO and Treasurer | A | — | — |
| 2025-02-11 | Robyn C Davis | Director | A | — | — |
| 2025-02-11 | Dipal Doshi | Director | A | — | — |
| 2025-02-11 | Tina Susan Nova | Director | A | — | — |
| 2025-02-11 | Erica McLaughlin | Director | A | — | — |
| 2025-02-11 | Alan J Malus | Director | A | — | — |
| 2025-02-11 | William L Cornog | Director | A | — | — |
| 2025-02-11 | Quentin Koffey | Director | A | — | — |
| 2025-02-11 | Frank Casal | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,622,450 | — |
| — | CEO | 436,953 | — |
| — | President and CEO | 213,193 | — |
| — | EVP & Chief Financial Officer | 123,860 | — |
| — | SVP, General Counsel, Secy. | 112,564 | — |
| — | Director | 111,818 | — |
| — | Director | 105,393 | — |
| — | Director | 85,175 | — |
| — | EVP, CFO and Treasurer | 79,655 | — |
| — | Chief Strategy & New Business | 74,868 | — |
| — | SVP, Gen Counsel & Secretary | 68,728 | — |
| — | Director | 42,750 | — |
| — | Director | 41,134 | — |
| — | SVP and GM, Multiomics | 38,755 | — |
| — | Director | 33,627 | — |
| — | SVP and CHRO | 31,953 | — |
| — | SVP, GM Life Science Products | 31,438 | — |
| — | EVP & Chief Operating Officer | 29,467 | — |
| — | SVP & GM, SMS | 23,974 | — |
| — | EVP, Chief Financial Officer | 23,892 | — |
| — | Director | 22,521 | — |
| — | Director | 21,803 | — |
| — | Director | 17,035 | — |
| — | Director | 15,772 | — |
| — | Director | 13,042 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AZTA quote page; the site-wide leaderboard is on the insider transactions hub.